You are here

Prefilled Syringe Fill/Finish Services Industry Assessment 2020-2030 - Increase in Development Initiatives for Vaccines due to COVID-19 Pandemic Significantly Raising Demand for Prefilled Syringes

DUBLIN, May 21, 2020 /PRNewswire/ -- The "Prefilled Syringe Fill / Finish Services Market, 2020-2030" report has been added to's offering.

This report features an extensive study of the current market landscape and future opportunities for contract service providers offering fill finish services for prefilled syringes. The study features an in-depth analysis of the key drivers and trends related to this evolving domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall pharmaceutical and biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs, and outsourcing trends related to fill/finish operations, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time period 2020-2030.

Our year-wise projections of the current and future opportunity have further been segmented on the basis of:

  • [A] scale of operation (preclinical, clinical and commercial)
  • [B] key geographical regions (North America (the US), Europe (the UK, France, Italy, Spain, Germany and rest of Europe) and Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific)
  • [C] type of drug molecule (small molecules and biologics)
  • [D] key therapeutic areas (blood disorders, infectious diseases, metabolic disorders, oncology disorders, neurological disorders, autoimmune disorders and others)
  • [E] syringe barrel material (glass and plastic)
  • [F] number of barrel chambers (single chamber and dual chamber)

Among drug delivery devices, prefilled syringes represent one of the fastest growing primary packaging formats, which are also designed for dose administration. In fact, over the past ten years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in an increased consumption of prefilled syringes, by approximately three fold. The sustained preference for such products can be attributed to the fact that prefilled syringes are safe and easy-to-use, and current variants are designed with provisions to reduce dosing errors, the risk of occlusions, extravasation and phlebitis.

Owing to the aforementioned benefits, several injectable drugs (such as Humira, Enbrel, Avastin, PREVNAR 13, ALPROLIX and Benefix), diluents and other products requiring parenteral administration, are packaged in prefilled syringes. In fact, over the past seven years, around 90 drugs have been approved in combination with prefilled syringes across different geographies, including the North America, Europe and Asia-Pacific. Moreover, several clinical-stage drugs are being evaluated in combination with prefilled syringes, across different phases of development.

Owing to the recent COVID-19 pandemic, an increase in the development initiatives for the vaccines is likely to be witnessed in the near future. This is expected to significantly raise the demand for prefilled syringes, providing an additional impetus to the overall fill/finish services market.

The filling of sterile drugs into prefilled syringes (and other primary drug containers) is considered to be one of the most crucial steps in the pharmaceutical production process. Proper fill/finish operations, carried out under aseptic conditions, is a necessity for not only maintaining pharmacological efficacy and quality, but also ensuring end user safety. The prefilled syringe filling operation is considered complex as it requires close monitoring of both the syringe fill volume as well as the headspace between the liquid in the syringe and the bottom of the plunger.

Additionally, the rise in complexity of small molecule APIs and the increasing diversity of biologic drugs have also contributed towards the demand of advanced aseptic fill/finish operations. A number of small-sized companies and some large companies have outsourced their fill/finish operations to contract service providers. According to the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, biomanufacturers have been shown to outsource over 30% of their fill/finish operations.

With the increase in the demand for prefilled syringes, along with the growing complexity of fill/finish processes, the outsourcing of these operations is likely to increase further in the future. Currently, over 100 companies are actively providing fill/finish services for prefilled syringes.

In order to cope up with the current and future market demand, service providers are actively investing in expanding their existing infrastructure and capabilities; companies are also expanding their client reach through service agreements in the past few years. Given that around 55% of drug candidates in the global R&D pipeline are injectables, the opportunities for prefilled syringe developers / manufacturers and affiliated service providers is anticipated to continue to grow over the next decade.

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract fill/finish services for prefilled syringes, along with analyses based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of the headquarters, location of fill/finish facilities, type of drug molecule (small molecule and biologic), syringe barrel material (glass and plastic), syringe fill volume and additional services offered (drug formulation, regulatory support, labelling and packaging, terminal sterilization, quality control, storage and logistics). In addition, the chapter includes details on prefilled syringe fill/finish installed capacity of the service providers.
  • Tabulated profiles of key players (shortlisted based on a proprietary criterion) across key geographies, such as North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its overall service portfolio, fill/finish facilities, financial performance (if available), and details on recent developments as well as an informed future outlook.
  • An analysis of the recent developments (since 2015) pertaining to contract fill/finish services, based on various parameters, such as year of development, type of activity/development (collaboration and expansions), scale of operation of the project, location of expanded facility, type of drug molecule involved, additional services offered and most active players (based on the number of instances of collaborations/expansions).
  • An estimate of the global, contract fill/finish capacity of prefilled syringes, by taking into consideration the capacities of various fill/finish service providers (as available on respective company websites), collected via secondary and primary research. The study examines the distribution of number of prefilled syringe units and volume of drug filled, based on the company size of manufacturer (small-sized, mid-sized and large), scale of operation (preclinical / clinical and commercial), location of headquarters and fill/finish facilities (North America, Europe and Asia-Pacific) and type of drug molecule (small molecule and biologics).
  • An informed estimate of the annual demand for fill/finish of prefilled syringes (in number of units), taking into account the marketed drugs available in prefilled syringes and other relevant parameters, such as target patient population, dosing frequency and dose strength. The study provides the distribution of the annual demand, based on the geography (North America (US), Europe (UK, France, Italy, Spain, Germany and rest of Europe), Latin America (Brazil, Mexico, Argentina and rest of Latin America), Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and rest of the Middle East)), type of drug molecule (small molecule and biologics), therapeutic area (blood disorders, infectious diseases, metabolic disorders, oncological disorders and others), syringe barrel material (glass and plastic) and number of barrel chambers (single chamber and dual chamber).
  • A detailed demand and supply assessment of geographies, based on a number of parameters, such as the number of prefilled syringe combination product developers, number of prefilled syringe manufacturers, number of prefilled syringe fill/finish service providers, number of prefilled syringe fill/finish facilities, capacity and demand of prefilled syringes in that particular geographical region.
  • An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe fill/finish service providers, based on different parameters, such as pipeline strength, number of target therapeutic indication(s), type of drug molecule, year of establishment, company size and location of the headquarters of the company.
  • A discussion on the potential growth areas, such as growing injectable drugs pipeline, increasing fill/finish outsourcing operations, rising preference of self-medication, increasing popularity of prefilled syringes and technological advancements in aseptic fill/finish processes.
  • A review of the landscape of prefilled syringe manufacturers, featuring a list of key prefilled syringes and their manufacturers, analyzed based on a number of relevant parameters, such as syringe barrel material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) barrel volume, year of establishment, company size and location of the headquarters of manufacturers.

To account for the uncertainties associated with the fill/finish of prefilled syringes and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals
  • Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
  • Jesse Fourt, Design Director, IDEO
  • Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene
  • Anonymous, Associate Director, Head of Process Sciences Formulation and fill/finish, a large CMO

Companies Mentioned

  • AbbVie Contract Manufacturing
  • Aguettant
  • AJ Biologics
  • Ajinomoto Bio-Pharma Services
  • Akron Biotech
  • Akums Drugs and Pharmaceuticals
  • Alanza
  • Alcami
  • Alfasigma
  • Alkermes
  • AMRI
  • APL
  • Aristopharma
  • Austrianova
  • Automated Systems of Tacoma
  • Axcellerate Pharma
  • Bahrain Pharma
  • Baxter
  • Becton Dickinson
  • Berkshire Sterile Manufacturing
  • Beximco Pharma
  • Bio Elpida
  • Biocon
  • BioConnection
  • Biomedical Advanced Research and Development Authority
  • BioPharma Solutions
  • Biotech Vision Care
  • BirgiMefar
  • Boehringer Ingelheim BioXcellence
  • Bryllan
  • Catalent Biologics
  • Cenexi
  • Cerium Pharmaceuticals
  • CinnaGen
  • Ciron Drugs and Pharmaceutical
  • Cobra Biologics
  • Consort Medical
  • Cook Pharmica
  • CordenPharma
  • Dalton Pharma Services
  • Delpharm
  • Dhruv Life sciences
  • DM Bio
  • EirGen Pharma
  • Emcure Pharmaceuticals
  • Emergent BioSolutions
  • Eurofins BioPharma
  • European Medical Contract Manufacturing
  • EVER Pharma
  • ExCellThera
  • Fresenius Kabi Contract Manufacturing
  • Gadea Pharmaceutical Group
  • Genovior Biotech
  • Gerresheimer
  • Gland Pharma
  • GP Pharm
  • Grand River Aseptic Manufacturing
  • GlaxoSmithKline
  • Gulf Biotech
  • Health Biotech
  • Healthcare Pharmaceuticals
  • Hetero Drugs
  • Hisun Pharmaceuticals USA
  • IDEO
  • IDT Biologika
  • Injectalia
  • Intas Pharmaceuticals
  • Integrity Bio
  • Irisys
  • Italfarmaco
  • Kemwell Biopharma
  • Kilitch Healthcare
  • KP Pharmaceutical Technology
  • Lifecore Biomedical
  • LSNE Contract Manufacturing
  • Lubrizol Life Science Health
  • Medefil
  • Mithra
  • Mitsubishi Gas Chemical
  • Mycenax Biotech
  • Nipro
  • Northway Biotechpharma
  • Nova Laboratories
  • Ology Bioservices
  • OmniChem
  • Ompi
  • Oncotec Pharma Produktion
  • Patheon
  • PCI Pharma Services
  • Pfizer CentreOne
  • Pfizer Injectables
  • Pharmaceutics International
  • Pierre Fabre
  • PiSA Farmacutica
  • Polpharma Biologics
  • Praxis Pharmaceutical
  • Precision Ocular Metrology
  • PrimaPharma
  • PYRAMID Laboratories
  • Reliance Life Sciences
  • Rentschler Biopharma
  • Rompharm
  • Rovi CM
  • Samsung Bioepis
  • Samsung Biologics
  • Sandoz
  • Saudi Biotech Manufacturing
  • Schott
  • Schott Kaisha
  • ScinoPharm
  • Selecta Biosciences
  • Sewa Medicals
  • Shandong Pharmaceutical Glass
  • Shandong Weigao
  • Sharp Corporation
  • SHL Group
  • Siegfried
  • Singota Solutions
  • Sovereign Pharma
  • Square Pharmaceuticals
  • Sunshine Health Products
  • Swissfillon
  • Symphogen
  • Syngene
  • Taisei Kako
  • Taiyo Yakuhin
  • Tanvex BioPharma
  • Terumo
  • Tolmar
  • TriPharm Services
  • Unicep
  • United States Army Medical Materiel Development Activity
  • USV
  • Vanrx Pharmasystems
  • VELIT Biopharmaceuticals
  • Vetter Pharma
  • VxP Biologics
  • West Pharmaceuticals
  • Wockhardt
  • Zen Pharma

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets